<DOC>
	<DOCNO>NCT01690975</DOCNO>
	<brief_summary>This single-center , randomize , third party blind , placebo control , dose escalation study benzonatate follow single dose administration . The primary oobjective ass safety tolerability increase oral dos benzonatate follow single dose administration healthy male female subject .</brief_summary>
	<brief_title>Benzonatate Dose Tolerance Study</brief_title>
	<detailed_description />
	<mesh_term>Benzonatate</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG , clinical laboratory test . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>